Summary PointsTime-sensitive access to unapproved experimental interventions should be permitted on humanitarian grounds when patients or communities are facing death or irreversible...
Summary Points:The evidence base underpinning clinical practice is deeply flawed.There must be better value gained from resources invested in medical research.We make...
Summary Points:Historically, the impact of many health professional training initiatives in low-income countries has been limited by narrow focus on a small set of diseases,...
Summary PointsThe international response to the West African Ebola virus disease epidemic has exemplified the great potential of the global public health community. However,...
Summary Points:Spending on brand-name prescription medications, particularly brand-name biologic drugs, continues to increase.Considerable savings and improvements in medication...
Companies that can demonstrate patient outcomes will hold a distinct competitive advantage. To gain that advantage, they must know how to comply with HIPAA rule – or better...
Summary Points:Meaningful use is an incentive program sponsored by the US federal government that has provided more than US$25 billion to date to incentivize US healthcare...
This recent research identifies current and emerging regulatory and compliance needs of biotechnology, pharmaceutical, and medical device companies, as well as key capabilities...
Tougher competition and margin pressures create more challenges for the pharma industry in 2015. Changes in the payer landscape and practice centralization have turned pharmaceutical...
The biomedical research workflow is often a multi-dimensional process. Depending on the question you are trying to answer, the process my include surveying a new cell type...